Combining advanced volumetric imaging technology with deep learning, the Genius Digital Diagnostics System has reportedly shown a 28 percent reduction in false negatives for high-grade squamous intraepithelial lesions and other severe lesions in comparison to microscopic review.
The Food and Drug Administration (FDA) has granted 510(k) clearance to the Genius Digital Diagnostics System, an artificial intelligence (AI)-enabled digital cytology platform that may facilitate enhanced sensitivity for early diagnosis of cervical cancer.
While traditional cervical cancer screenings have involved microscopic review of samples from Pap smear testing, the Genius Digital Diagnostics System facilitates digital image review of these samples with a Genius Cervical AI algorithm that alerts clinicians to suspicious cells for further review, according to Hologic, the developer of the Genius Digital Diagnostics System.
Combining deep learning capability with advanced volumetric imaging technology, the Genius Digital Diagnostics System may facilitate earlier diagnosis of cervical cancer. (Image courtesy of Hologic.)
In comparison to microscopic review of Pap smear testing, Hologic noted that research has demonstrated a 28 percent reduction in false negatives for high-grade squamous intraepithelial lesions and other severe lesions with the Genius Digital Diagnostics System.
“Our technologies have had a tremendous impact on decreasing cancer rates in women, and we are incredibly excited by the promise of Genius Digital Diagnostics. The system delivers more actionable and accurate insights for laboratories and healthcare professionals to enhance patient care,” said Jennifer Schneiders, Ph.D., the president of diagnostic solutions at Hologic.
Can AI Facilitate Effective Triage for Supplemental Breast MRI After Negative Mammography Screening?
July 10th 2024The AISmartDensity software facilitated a cancer detection rate (CDR) with breast MRI that was nearly four times higher than the CDR previously reported in trials involving traditional breast density assessment.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Can AI Facilitate Improved Dual-Energy X-Ray Screening for Patients at High Risk of Osteoporosis?
June 28th 2024Out of 315 patients identified by artificial intelligence (AI) as being at high risk for osteoporosis, subsequent screening with dual-energy X-ray absorptiometry (DXA) in a randomized controlled trial revealed new-onset osteoporosis in 237 patients.
FDA Clears Pocket-Sized ECG System and AI Technology for Detection of Cardiac Conditions
June 27th 2024Using a reduced leadset and deep neural network algorithms trained on more than 175 million electrocardiograms, the KAI 12L technology reportedly detects up to 35 cardiac determinations, including acute myocardial infarction.